Acorda Therapeutics, Inc. ACOR reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents. The company …
Credit Suisse, an active trader of Mantra stock, became an 8.17 per cent owner of …
Pacira Pharmaceuticals (PCRX): PCRX stock is up 3.3% today. Acorda Therapeutics (ACOR): ACOR stock is up 2.9% today. Ligand Pharmaceuticals Inc (LGND): LGND stock is up 2.7% today. Ironwood Pharmaceuticals (IRWD): IRWD …
By Jake King When Mr. Deryugin penned his original thoughts on Acorda Therapeutics (NASDAQ:ACOR) in mid-2013, the stock traded around $38. While investors heeding his advice sit slightly in the green today, we believe the thesis holds …
Bob East has led Mantra since 2007. Paul Harris Accor will take effective control of Mantra Group on May 23, which will also be the last day Mantra shares will trade on the Australian Stock Exchange. The implementation date – when …
UBS kept a "buy" rating on Accor shares, while Bernstein has an "underperform" rating on the stock. Previous acquisitions under Bazin, who took over in 2013, include Toronto-based Fairmont Raffles Hotels International, owner of London's …
Acorda Therapeutics (ACOR): ACOR stock is up 1.6% today ... Article printed from InvestorPlace Media, https://investorplace.com/2015/08/hottest-healthcare-stocks-now-mdco-scmp-cemp-acor-mdco-scmp-cemp/.